DFFN News and Press, Diffusion Pharmaceuticals Inc. From 12/16/22

LifeSci Special Opportunities Master Fund Announces Support for Diffusion’s Ongoing, Board-led Strategic Review Process and for Diffusion’s Nominees at 2022 Annual Meeting New Director to be Appointed to Diffusion Board if Strategic Transaction Not Completed by mid-2023 ...

Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process Diffusion received bids from more than 15 companies participating in review process LifeSci invited to participate in review process on sam...

Sets the Record Straight on Diffusion’s Misleading Narrative and Raises Concerns about a Troubling Pattern of Entrenchment and Lack of Accountability on the Board Has Nominated a Slate of Highly Qualified Directors NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) --...

Diffusion Pharmaceuticals press release ( NASDAQ: DFFN ): Q3 GAAP EPS of -$1.37 beats by $0.69 . As of September 30, 2022, Diffusion had $25.9M in cash, cash equivalents, and marketable securities, which the Company currently expects will enable it to fund its ope...

Announced Thorough Evaluation of a Range of Potential Strategic Opportunities Continued GBM Study Start-up Activities Ended Quarter with $25.9 million in Cash, Cash Equivalents and Marketable Securities CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Di...

Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of Investment Bank LifeSci Capital LifeSci-affiliated Fund Commences Proxy C...

Diffusion Pharmaceuticals ( NASDAQ: DFFN ) said it will undertake a strategic review to evaluate options which could include a sale of the company. As part of its ongoing efforts to identify acquisition and partnership transactions which complement its develo...

CHARLOTTESVILLE, Va., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver oxygen to areas ...

H.C. Wainwright upgraded clinical-stage biotech Diffusion Pharma ( NASDAQ: DFFN ) to Buy from Neutral on Tuesday, citing the company's Q2 2022 update on its lead candidate Trans Sodium Crocetinate (TSC) in glioblastoma multiforme (GBM). Following positive data for TSC fr...

Diffusion Pharmaceuticals press release ( NASDAQ: DFFN ): Q2 GAAP EPS of -$2.06 misses by $0.02 . As of June 30, 2022, Diffusion had $28.5M in cash, cash equivalents, and marketable securities, which the company currently expects will enable it to fund its operati...